Freiburg Medical Laboratory ME LLC, P.O.Box 3068, Dubai Tel: 04 396 2227 Fax: 04 396 2228

Valproic Acid, Dipropylacetate

General:

Valproic acid is applied in pycnoleptic absences and in grand-mal attacks. After an oral dose valproic acid is eliminated hepatically (90%) and renally (5%.) with a half-life of 8-15 h. A steady state is obtained after 2 – 3 days. Possible therapy side effects are: liver toxicity with carnitine impairment, pancreatitis, thrombocytopenia, hyperammonemia.

Medication containing valproic acid: Convulex, Ergenyl, Leptilan, Mylproin, Orfiril.

Indication:	Monitoring
Material:	1 ml serum
Stability:	7 days (capped) at 2 to 8°C
TAT:	same day, FML
Method:	MEIA
Units:	mg/l
Ref.- range:	50.0 - 100.0
Note:	During intake frequent monitoring of liver function, free and total carnitines, coagulation factors and thrombocytes is recommended.

The following test is available:

- **Valporic acid (Dipropylacetate)**

Material:	1 ml serum
TAT:	same day, FML
Method:	EIA

For complete list of laboratory test offered at Freiburg Medical Laboratory, please visit http://www.fml-dubai.com/parameter-listings/

Updated 02/04/2022